Webcast Library February 12, 2015

Webinar: Teva v. Sandoz SCOTUS Decision

On January 20, 2015, the U.S. Supreme Court issued its decision in Teva Pharms. USA, Inc. v. Sandoz, Inc., No. 13-854, which addressed an issue with widespread importance in the interpretation of patents: whether a district court’s factual findings in support of its construction of a patent claim term may be reviewed de novo or only for “clear error.” In a 7-2 decision authored by Justice Stephen Breyer, the Supreme Court held that, when reviewing a district court’s factual findings made in the course of its claim construction, the Federal Circuit must apply the clear-error standard of review. That holding reverses nearly two decades of practice before the appellate court.

At our recent webinar William M. Jay, who argued the case for Teva, and Nicholas K. Mitrokostas of Goodwin Procter LLP discussed:

  • A review of the case law and legal proceedings leading up to these decisions
  • A summary of the opinion and the Supreme Court’s adoption of “clear error” review for factual findings made in the course of claim construction
  • The potential impact of the Teva decision on future patent litigation and appeals

Download the slides from this webinar

To access the webinar recording, please click below.